2. Antibody-drug Conjugate/ADC Related Cell Cycle/DNA Damage Apoptosis
  3. Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis
  4. Ifinatamab deruxtecan

Ifinatamab deruxtecan  (Synonyms: DS-7300a; MABX-9001a; I-DXd)

製品番号: HY-P3371 純度: 98.98%
COA 取扱説明書 Technical Support

Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Ifinatamab deruxtecan

Ifinatamab deruxtecan 構造式

CAS 番号 : 2484870-92-8

容量 価格（税別） 在庫状況 数量
1 mg $480 在庫あり
5 mg $1180 在庫あり
10 mg $1880 在庫あり
25 mg $3500 在庫あり
50 mg $5600 在庫あり
100 mg   お問い合わせ  
200 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

Ifinatamab deruxtecan 関連抗体

Top Publications Citing Use of Products

Topoisomerase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Topoisomerase Topo I Topo II DNA gyrase

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects[1][2][3][4]

IC50 & Target[2]

Topoisomerase I

 

体外実験

Ifinatamab deruxtecan inhibits the growth of B7-H3-expressing cancer cells in vitro, but not of B7-H3-negative cancer cells[1].
Ifinatamab deruxtecan (6 days) potently and selectively inhibits the growth of B7-H3-expressing RH-41 and MFE-280 cancer cells in vitro, with no activity against B7-H3-negative CCRF-CEM cells[2].
Ifinatamab deruxtecan (10 μg/mL; 72 hours) induces DNA damage and apoptosis in B7-H3-expressing RH-41 cancer cells in vitro[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ifinatamab deruxtecan 関連抗体

Western Blot Analysis[2]

Cell Line: Human rhabdomyosarcoma (RH-41) cells
Concentration: 10 μg/mL
Incubation Time: 72 h
Result: Induced phosphorylation of Chk1 (a DNA damage marker) in RH-41 cells. Induced cleavage of PARP (an apoptosis marker) in RH-41 cells.
Parmacokinetics
Species Dose Route T1/2 (Elimination)
Cynomolgus Monkey[2] 0.3 mg/kg i.v. 77.76 h
Cynomolgus Monkey[2] 1 mg/kg i.v. 122.64 h
Cynomolgus Monkey[2] 3 mg/kg i.v. 189.36 h
Cynomolgus Monkey[2] 10 mg/kg i.v. 115.44 h
体内実験

Ifinatamab deruxtecan (3-10 mg/kg; i.v.; days 0 and 14) exerts potent dose-dependent antitumor activity against rhabdomyosarcoma xenografts in mice, achieving 90% and 98% TGI at 3 mg/kg and 10 mg/kg, respectively[2].
Ifinatamab deruxtecan (0.3-3 mg/kg; i.v.; days 0 and 14) exerts potent antitumor activity against endometrial adenocarcinoma xenografts in mice, achieving 67% TGI at 0.3 mg/kg and complete tumor growth inhibition (100% TGI) at 1 mg/kg and 3 mg/kg[2].
Ifinatamab deruxtecan (1-10 mg/kg; i.v.; days 0 and 14) exerts potent dose-dependent antitumor activity against lung adenocarcinoma xenografts in mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CAnN.Cg-Foxn1nu/CrlCrlj (lung adenocarcinoma xenograft model)[2]
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: i.v.; days 0 and 14
Result: Achieved tumor growth inhibition (TGI) of 71% at 1 mg/kg compared to vehicle control group (P < 0.001).\nAchieved tumor growth inhibition (TGI) of 95% at 3 mg/kg compared to vehicle control group (P < 0.001).\nAchieved tumor growth inhibition (TGI) of 99% at 10 mg/kg compared to vehicle control group (P < 0.001).
臨床実験
CAS 番号
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Ifinatamab deruxtecan]
輸送条件

Shipping with dry ice.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション

純度: 99.29%

COA (231 KB) Others (331 KB) SEC-HPLC (187 KB)

取扱説明書 (2659 KB)
参考文献
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ifinatamab deruxtecan Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ifinatamab deruxtecan2484870-92-8DS-7300a MABX-9001a I-DXdAntibody-Drug Conjugates (ADCs)TopoisomeraseApoptosisAntibody-Drug Conjugatescynomolgus monkeysmetastatic castration-resistant prostate cancerpatient-derived xenograft mouse modelsB7-H3-expressing solid tumorsratstumor xenograftapoptosisB7-H3 (CD276)cancer cellsDNA topoisomerase IInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Ifinatamab deruxtecan
製品番号:
HY-P3371
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.